Jordan Kardos, PhD, MBA

Head of Computational Biology at Arda Therapeutics I lead Arda's AI platform development, target identification, target validation & indication expansion efforts.

Led the Oncology Early Development team within Clinical Bioinformatics, managing the team responsible for data analysis on all Ph1 Oncology trials -Ph1 study of GS-1811, an Anti-CCR8 Monoclonal Antibody (NCT05007782) -Ph1 study of GS-9716, an MCL1 small molecule inhibitor (NCT05006794) -Ph1 study of GS-4528, an IL2v (NCT05840224) -Ph1 study of GS-0201, a PARP1 small molecule inhibitor (NCT06167317) -Ph1 study of GS-2121, a Helios molecular glue degrader (NCT06532565) -Ph1 study of GS-9911, a DGKa small molecule inhibitor (NCT06082960)

-Led bioinformatic analysis on GS-1811, an anti-CCR8 antibody currently in Ph1 clinical trials, that informed decisions around identification of a mechanism of action, pharmacodynamics, and indication selection -Led the bioinformatic analysis of real-world data and associated multiomic data in partnership with Tempus Labs that has supported multiple internal oncology projects -Led the bioinformatic research characterization of Trodelvy (Sacituzumab govitecan) that has supported the identification of potential mechanisms of resistance and expanded indication selection -Developed internal single-cell and proteomic analysis pipelines for CITE-seq analysis for GS-9911, a DGKα inhibitor currently in Ph1 trials, to characterize target biology -Led the bioinformatic analysis of several research oncology projects across pre-exploratory, exploratory, and full project status, resulting in multiple FDA IND filings -Developed internal tools for the analysis of both public and proprietary multi-omics datasets for oncology research

-Led bioinformatic analysis on GS-1811, an anti-CCR8 antibody currently in Ph1 clinical trials, that informed decisions around identification of a mechanism of action, pharmacodynamics, and indication selection -Led the bioinformatic analysis of real-world data and associated multiomic data in partnership with Tempus Labs that has supported multiple internal oncology projects -Led the bioinformatic research characterization of Trodelvy (Sacituzumab govitecan) that has supported the identification of potential mechanisms of resistance and expanded indication selection -Developed internal single-cell and proteomic analysis pipelines for CITE-seq analysis for GS-9911, a DGKα inhibitor currently in Ph1 trials, to characterize target biology -Led the bioinformatic analysis of several research oncology projects across pre-exploratory, exploratory, and full project status, resulting in multiple FDA IND filings -Developed internal tools for the analysis of both public and proprietary multi-omics datasets for oncology research

-Identified and characterized the novel claudin-low subtype of muscle-invasive urothelial carcinoma, which has since been integrated into a consensus molecular classification of urothelial carcinoma. -Led the first molecular characterization of urachal adenocarcinoma that identified the prevalence of mutations associated with microsatellite instability and provided case study evidence for the efficacy of immune checkpoint inhibitors in urachal adenocarcinoma. -Developed and validated a Nanostring platform molecular subtype classifier of urothelial carcinoma that has improved translational access to clinical patient sample molecular subtyping -Contributed to clinical trial design and response biomarker identification in a phase II trial of palbociclib in patients with metastatic bladder cancer. -Contributed to the development and characterization of subtype-specific immunocompetent mouse models of urothelial carcinoma to characterize immune checkpoint inhibitor response in urothelial carcinoma.